Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG‐IFN α‐2a (40KD) (PEGASYS<sup>®</sup>)
Brian Bressler(University of British Columbia), E. Jenny Heathcote(University of Toronto), Ka Wang(Central South University), Joseph F. Grippo(Inflarx (Germany))
Cited by 15
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Rates of New or Missed Colorectal Cancers After Colonoscopy and Their Risk Factors: A Population-Based Analysis
|Gastroenterology|2007|627
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
|Gastroenterology|2015|478